Ποια είναι η τιμή για RegeneRx Biopharmaceuticals, Inc. (RGRX)

Η τιμή για RegeneRx Biopharmaceuticals, Inc. (RGRX) είναι $0.0007

Ποια είναι η κεφαλαιοποίηση αγοράς για RegeneRx Biopharmaceuticals, Inc. (RGRX)

Η κεφαλαιοποίηση αγοράς για RegeneRx Biopharmaceuticals, Inc. (RGRX) είναι $1.05K

RegeneRx Biopharmaceuticals, Inc. (RGRX) Τιμή και Κεφαλαιοποίηση Αγοράς

RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.

Η τιμή για RGRX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$3,595,757 $1.05K	NVDA	$5.383T	+513,679,631,777.65%
$2,954,557 $1.05K	AAPL	$4.423T	+422,079,554,882.38%
$2,778,874 $1.05K	GOOG	$4.160T	+396,982,040,069.30%
$2,446,876 $1.05K	MSFT	$3.663T	+349,553,715,007.09%
$1,931,165 $1.05K	AMZN	$2.891T	+275,880,768,095.10%

Η τιμή για RGRX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$3,595,757 $1.05K